The Company incurs costs associated with restructuring initiatives intended to improve operating performance, profitability, and working capital levels. Actions associated with these initiatives may include improving productivity, workforce reductions, and the consolidation of facilities.

As of March 31, 2023, the Company has identified restructuring actions which will result in additional charges of approximately $1.1 million, primarily in the next 12 months.


Future Estimated Restructuring Expense by Segment (in millions)
Medical		Industrial		Corporate		Total
$	0.6	$	0.4	$	0.1	$	1.1

The Company’s restructuring expenses are comprised of the following (in millions):


	Three Months Ended March 31, 2023
	Cost of revenue		Selling, general and administrative		Total
Severance and employee costs	$	—	$	1.2	$	1.2
Other(1)	—		0.2		0.2
Total	$	—	$	1.4	$	1.4


	Three Months Ended March 31, 2022
	Cost of revenue		Selling, general and administrative		Total
Severance and employee costs	$	0.1	$	0.9	$	1.0
Other(1)	—		1.0		1.0
Total	$	0.1	$	1.9	$	2.0

(1) Includes facilities, inventory write-downs, outside services, legal matters, and IT costs.

The following table summarizes restructuring expenses for each reportable segment (in millions):


	Three Months Ended
	March 31,
	2023		2022
Restructuring expenses:
Medical	$	0.3	$	1.5
Industrial	0.1		—
Corporate and other	1.0		0.5
Total	$	1.4	$	2.0

The following table summarizes the changes in the Company’s accrued restructuring balance, which are included in Accrued expenses and other current liabilities in the accompanying Condensed Consolidated Balance Sheets (in millions).


Balance at December 31, 2022	$	1.5
Restructuring charges	1.4
Payments	(0.6)
Adjustments	—
Balance at March 31, 2023	$	2.3